共查询到20条相似文献,搜索用时 15 毫秒
1.
N. Ortego-Centeno M. Muñoz-Torres J. Hernandez-Quero A. Jurado-Duce J. de la Higuera Torres-Puchol 《Calcified tissue international》1994,55(6):403-407
Smoking is related to decreased bone mass and increased risk of osteoporotic fractures. However, the harmful effects of smoking on bone have not been well characterized. The purpose of this study was to assess the repercussions of smoking on bone mass in premenopausal women, and the relationship between these effects and parameters of mineral metabolism and hormone profile. We measured bone mineral density (BMD) in 101 premenopausal women (47 smokers, 54 nonsmokers) with dualenergy X-ray absorptiometry (DeXA) of the proximal femur and lumbar spine. In a subgroup of the sample (16 smokers, 15 nonsmokers) we measured biochemical indicators of mineral metabolism and hormone profile. BMD in the femoral neck, Ward's triangle, and the intertrochanter region was significantly lower in smoker (P<0.05) than in nonsmokers. Concentrations of sex hormone-binding globulin were higher, and free testosterone index (FTI) was lower (P<0.05) in smokers. We found no significant differences between the groups in parameters of mineral metabolism. Concentrations of dehydroepiandrosterone sulfate and free testosterone index were directly correlated with values of BMD in different sites. Our findings show that smoking by premenopausal women is associated with decreased BMD and characteristic changes in the hormone profile. 相似文献
2.
H. Dobnig L. C. Hofbauer V. Viereck B. Obermayer-Pietsch A. Fahrleitner-Pammer 《Osteoporosis international》2006,17(5):693-703
Introduction Since the soluble receptor activator of the NF-κB ligand (sRANKL) as well as the endogenous anti-resorptive cytokine osteoprotegerin
(OPG) are produced by osteoblasts and given that these cells undergo significant changes during antiresorptive treatment,
we hypothesized that treatment with bisphosphonates (BP) would be accompanied by changes in serum OPG and sRANKL levels.
Methods In a prospective, randomized controlled trial of previously untreated postmenopausal women with osteoporosis, oral BP therapy
(daily doses of either 10 mg alendronate or 5 mg risedronate) in combination with calcium/vitamin D was compared to calcium/vitamin D
treatment alone (control group). Follow-up at 2, 6 and 12 months was completed for 56 patients. Standardized spinal X-rays
were performed at baseline, and DEXA measurements at the femoral neck and trochanter were made at baseline and after 1 year.
Serum OPG and sRANKL levels were measured with a polyclonal antibody-based ELISA system.
Results After 1 year, there was a non-significant loss in neck and trochanteric bone mineral density (BMD) in the CTR group and a
mean increase of 3.3% and 4.6% in the combined BP group (both p<0.0001), respectively. Serum levels of C-terminal telopeptides of type I collagen (sCTX) and osteocalcin decreased by 12%
and 10% at 12 months in the CTR group and by 43% and 23% in the combined BP group, respectively (all significant). OPG serum
levels in the CTR group decreased significantly by 9% at 2 months (p<0.005) and remained below pre-treatment levels at later time points. Both the alendronate- and risedronate-treated patient
groups showed unaltered OPG levels after 2 months, but they had significantly increased serum levels at 6 and 12 months. Levels
of sRANKL were unchanged throughout the treatment period. Univariate regression analysis demonstrated that changes in serum
OPG levels after 12 months of BP treatment were positively and better correlated to BMD changes (trochanter: r= 0.59, p<0.0001; neck: r= 0.50, p<0.001) than those of sCTX, which showed the expected negative correlation to BMD change (trochanter: r= –0.35, p=0.03; neck: r= –0.23, p=0.16). With multiple regression analyses at 12 months, R2 values for 1-year changes in trochanteric BMD of 0.33 (OPG alone) and 0.23 (sCTX alone) were significantly improved to the
0.57 when OPG and sCTX changes were combined (p<0.001). Results for the femoral neck were also statistically significant R2=0.35, p<0.001). BMD and OPG changes in the CTR group were not correlated with each other.
Conclusions We conclude that with BP treatment, changes in serum OPG levels, unlike changes in sCTX levels, are positively correlated to changes in BMD response. The BP-related changes in serum OPG levels during treatment could result from effects
on osteoclastogenesis and osteoclast apoptosis as well as from a direct stimulatory effect on osteoblastic OPG production.
These changes in OPG levels may be used to predict the individual response of patients to BP treatment. 相似文献
3.
《Joint, bone, spine : revue du rhumatisme》2022,89(5):105373
ObjectiveOsteoporosis is a complication after allogenic stem cell transplantation (alloSCT). The purpose of this study was to assess changes in bone mineral density (BMD) 6 months and 3 years after alloSCT, as well as predictors of bone loss.MethodsA longitudinal, prospective, single-center study was conducted at Lille University Hospital between 2005 and 2016. Clinical, biological, radiologic (thoracic and lumbar spine) and densitometric (DXA) assessments were carried out at baseline (pre-transplant), 6 months and 3 years. Patients with myeloma were not included.ResultsTwo hundred and fifty-eight patients were included (144 men). Among them, 60.1% had leukemia and 65.8% of them, acute myeloid leukemia. At baseline, 6 months and 3 years, DXA-confirmed that osteoporosis was observed in 17%, 22.8% and 17.5% of the patients, respectively, mainly at the femoral neck. At baseline, 6 months and 3 years, 9 (8.5%), 53 (21.5%) and 38 (16.7%) patients, respectively, were receiving anti-osteoporotic treatment. From baseline to 6-month follow-up, BMD decreased significantly (p < 0.001) at the lumbar spine (?36 [95%CI; ?51 to ?20] mg/cm2 of hydroxyapatite), femoral neck (?43 [95%CI; ?57 to ?29] mg/cm2 of hydroxyapatite) and total hip (?53 [95%CI; ?68 to ?39] mg/cm2 of hydroxyapatite). From 6-month to 3-year follow-up, a significant increase in BMD was observed at the lumbar spine only (+31 [95%CI; 20 to 42] mg/cm2 of hydroxyapatite, p < 0.001). At all 3 sites, changes in BMD did not differ between patients treated or untreated by anti-osteoporotic treatment from 6-month to 3 year follow-up. Incident fractures were found in 4.1% and 5.7% of the patients at 6 months and 3 years, respectively. Between baseline and 6 months, bone loss at all 3 sites was associated with corticosteroid intake. At the total hip, 23.3% of the decrease in BMD from baseline to 6 months was due to an active hematological disease (p < 0.05), a bone marrow stem cells (p < 0.01) and a corticosteroid intake (p < 0.01).ConclusionOur study found evidence of bone fragility in alloSCT patients. Low BMD persisted at the hip 3 years after transplantation due to slower improvement at this site. 相似文献
4.
柴瑛 《中国骨质疏松杂志》2012,18(2):106-108
目的探讨老年男性骨质疏松患者血清胰淀素(Amylin)水平的变化及其与骨密度(BMD)及骨转换生化指标的关系。方法采用酶联免疫法(ELISA)测定89例老年男性骨质疏松患者和50例正常男性老年人血清Amylin、骨碱性磷酸酶(BAP)、骨钙素(BGP)、I型胶原氨基末端肽(NTX),采用美国NORLAND XR-46 Excell-plus双能X线骨密度测定仪分别测定正位腰椎(L2-L4)及左侧股骨颈BMD。结果老年男性骨质疏松患者正位腰椎及左侧股骨颈BMD、血清Amylin、BAP、BGP水平较正常男性老年人明显降低(均P<0.01),血清NTX水平较正常男性老年人明显升高(P<0.01)。老年男性骨质疏松患者血清Amylin水平与患者正位腰椎及左侧股骨颈BMD、血清BAP、BGP水平呈明显正相关(r=0.598,r=0.652,r=0.576,r=0.584,均P<0.01),与患者血清NTX水平呈明显负相关(r=-0.673,P<0.01)。结论血清胰淀素水平降低在老年男性骨质疏松的发病中可能发挥重要作用。 相似文献
5.
Rochira V Zirilli L Madeo B Aranda C Caffagni G Fabre B Montangero VE Roldan EJ Maffei L Carani C 《BONE》2007,40(6):1662-1668
The relative contribution of each sex steroid (i.e. estrogen and androgen) on bone in men and the relationships among sex steroids and changes in BMD and bone strength are still unknown. A defective BMD of bone tissue is constantly present in men with aromatase deficiency. This study evaluates the effects of different regimens of treatment with sex steroids over 7.3 years follow-up on BMD in an adult man affected by aromatase deficiency and by a concomitant mild hypogonadism, as previously described. The aim of the study is to provide additional data on the relative roles of androgens and estrogens in male bone metabolism. The effects of testosterone (T) treatment alone and estrogen (tE2) treatment alone as well as the effects of the combined treatment with testosterone and estradiol (T plus tE2) on areal BMD (aBMD) at dual-energy X-ray absorptiometry (DXA) and the effects of T plus tE2 on volumetric BMD (vBMD), particular at cortical site, measured by peripheral quantitative computed tomography (pQCT), are investigated. Hormones and markers of bone turnover were monitored during all phases of the study. Treatment with tE2 normalized serum estradiol, but only the combined treatment with T plus tE2 normalized both serum estradiol and testosterone. Markers of bone turnover reached a pattern close to normality during T plus tE2. The aBMD was little modified by T, but increased more during tE2. T plus tE2 resulted in a further increase in both aBMD at DXA and vBMD at pQCT. Cortical thickness increased during T plus tE2 both in radius and tibia. Only the combined treatment led to optimal parameters of aBMD suggesting that testosterone needs estrogens as a permissive factor for a direct androgen anabolic action on bone in men. 相似文献
6.
Yilmaz D Ersoy B Bilgin E Gümüşer G Onur E Pinar ED 《Journal of bone and mineral metabolism》2005,23(6):476-482
Puberty has a key role in bone development. During puberty, several nutritional and hormonal factors play a major role in
this process. The aim of this study was to determine the changes in areal bone mineral density (BMD), gonadal steroids, bone
formation markers, and growth parameters in healthy Turkish pubertal girls and boys at different pubertal stages. In additional,
we aimed to detect the relationship between BMD, sex steroids, and growth parameters, and to reveal the most important determinant
of BMD in the pubertal period. BMD of the lumbar spine and total body was performed by dual-energy X-ray absorptiometry (Lunar
DPX series) in 174 healthy pubertal children (91 girls, 83 boys), aged 11–15 years. Height and weight were measured. Pubertal
stages were assesed. Bone formation markers and gonadal steroids were measured. BMD values significantly increased until stage
IV in girls. In boys, BMD values also increased during puberty (P < 0.05), but it was significantly higher in stage IV compared with that in other pubertal stages (P < 0.01). Testosterone levels increased until stage IV in both sexes, particularly in boys. Estrogen levels significantly
increased during puberty in girls, whereas it was significantly higher at stage IV in boys (P < 0.001). Bone-specific alkaline phosphatase (BAP) level was higher in early and midpuberty, and decreased in late puberty
in girls (P < 0.001). BAP level was higher in stage IV in boys. Osteocalcin level was shown not to change significantly in pubertal stages.
There was a modest correlation between BMD values and estrogen and testosterone levels in boys. In girls, there was a correlation
between BMD values and estrogen levels only (P < 0.05). Weight was significantly associated with BMD in both sexes (P < 0.05). Estrogen had a significant influence on BMD in boys and girls. In conclusion, bone mass increased throughout puberty
in both sexes. Peak bone mass was not achieved in girls, but was obtained at stage IV in boys. Bone formation markers were
good predictors of bone mass in girls, but not in boys. Estrogen level made the greatest contribution to bone mineral acquisition
in boys and girls. The achievement of peak bone mass was sustained by estrogen in boys. The major independent determinant
of BMD in both sexes was weight. 相似文献
7.
[目的]观察补肾密骨片结合经皮自体骨髓移植对骨折延迟愈合治疗后的骨密度和生物力学性能影响。[方法]预制新西兰大耳白兔骨延迟愈合模型,将75只兔随机分为四组:A组20只,饲料中加入补肾密骨片,骨延迟愈合区注入自体红骨髓2ml;B组20只,饲料中加入补肾密骨片,骨延迟愈合区不注入自体红骨髓;C组20只,饲料中不加补肾密骨片,骨延迟愈合区注入自体红骨髓;D组15只,造成骨延迟愈合模型后,饲料中不加补肾密骨片,骨延迟愈合区不注人自体红骨髓。治疗后12周处死动物取材,行骨密度及生物力学测试。[结果]骨密度及生物力学测试均显示A组骨愈合优于B、C、D组。[结论]补肾密骨片结合经皮自体骨髓移植治疗骨折延迟愈合的骨组织的骨密度及生物力学强度优于单一骨髓移植或中药治疗。 相似文献
8.
El Maghraoui A Ouzzif Z Mounach A Ben-Ghabrit A Achemlal L Bezza A Ghozlani I 《BONE》2011,49(4):853-857
Objective
To examine the association between oestradiol (E2), testosterone (T), SHBG levels and vertebral fractures' (VFs) prevalence in asymptomatic men.Methods
The study cohort consists of a population of 112 consecutive men (mean ± SD (range) age, weight and BMI were 62.9 ± 9.2 (41–84) years, 75.0 ± 13.8 (45–120) kgs and 26.4 ± 4.7 (18.0–39.6) kg/m2, respectively). Lateral vertebral fracture assessment (VFA) images and scans of the lumbar spine and proximal femur were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genant semiquantitative approach and morphometry. Serum levels of T, E2, CTx and osteocalcine were measured. Free androgen index (FAI) and free estradiol index (FEI) were calculated respectively from the ratio of serum T and E2 to SHBG.Results
Among the 112 men, 38 (33.9%) had densitometric osteoporosis, and on VFA, VFs were identified in 60 (53.5%): 24 men had grade 1 and 36 had grade 2 or 3 VFs (32.1%). Men with VFs weighted less and had a statistically significant lower lumbar spine and total hip BMD and T-scores than those without a VFA-identified vertebral fracture. Levels of osteocalcine, CTx, and SHBG were statistically higher in men with grades 2 and 3 VFs than men with grade 1 VFs and those without VFs whereas FAI and FEI levels were significantly lower. Comparison of patients according to quartiles of SHBG levels showed that men in the highest quartile were older, had a lower lumbar spine and total hip BMD and a higher prevalence of osteoporosis and VFs. They had also higher levels of CTx. Stepwise regression analysis showed that the osteoporotic status and SHBG was independently associated to the presence of VFs.Conclusion
Men with asymptomatic densitometric VFs have lower BMD than subjects without VFs. They have evidence of higher SHBG levels and hence lower free sex steroids as well as increased bone resorption. This study confirms that BMD and CTx are the most important determinant of asymptomatic VFs, and that SHBG is an independent risk factor that must be taken into account. 相似文献9.
Y. Yamada S. Takahashi T. Fujimura H. Nishimatsu A. Ishikawa H. Kume K. Tomita T. Takeuchi T. Kitamura 《Osteoporosis international》2008,19(3):321-327
Summary Our study and previous reports suggest that castration results in increased bone turnover and lowered BMD and that these changes
might be attenuated by anti-androgens, such as BL and EMP.
Introduction Recent studies have shown that castration for PC decreases bone mineral density (BMD), while estrogen therapy or bicalutamide
(BL) monotherapy maintains BMD. However, the effect of combined androgen blockade (CAB) on bone turnover is not well studied.
Methods A total of 204 men were evaluated in the study (control group: n = 56, castration group: n = 102, ‘CAB with BL’ group: n = 22, ‘CAB with estramustine phosphate (EMP)’ group: n = 24). We measured steroid hormone levels, BMD (measured at one-third distal radius), bone turnover markers (levels of urinary
N-telopeptide cross links of type 1 collagen (u-NTx) and deoxypyridinoline (u-DPD), serum concentrations of osteocalcin (OC))
in order to assess differences between groups.
Results The BMD % Z score of the castration group was significantly lower than that of the control group or the ‘CAB with EMP’ group
(90.6% vs. 95.5%, 98.6%; p < 0.042, p < 0.044, respectively). Levels of u-NTx, u-DPD, OC of the castration group were the highest followed by the control group,
then the ‘CAB with BL’ group and the ‘CAB with EMP’ group.
Conclusions Our study and previous reports suggests that castration results in increased bone turnover and lowered BMD and that these
changes might be attenuated by anti-androgens, such as BL and EMP. 相似文献
10.
Vincent M. Brandenburg Markus Ketteler Nicole Heussen Dirk Politt Rolf D. Frank Ralf Westenfeld Thomas H. Ittel Jürgen Floege 《Osteoporosis international》2005,16(12):1611-1620
The influence of circulating sex hormones and gender on the bone mineral density (BMD) in long-term renal transplant recipients needs further investigation. We performed a retrospective analysis of lumbar BMD between 6 years and 20 years after renal transplantation. In 67 patients (47±12 years, 38 male) with a minimum interval of 72 months after transplantation, lumbar BMD measurements (dual energy X-ray absorptiometry) were performed (=complete cohort). Thirty-one patients (=longitudinal cohort) underwent at least three serial BMD measurements (mean follow-up 39±18 months, start at 86±22 months). All patients received prednisolone. In the complete cohort, BMD was significantly reduced in comparison to young healthy (mean T -score –1.33±1.40) and age-matched controls (mean Z -score –0.91±1.45) at 88±31 months ( p <0.05). Osteopenia or osteoporosis were present in two-thirds of patients. In the longitudinal cohort, a mean annual lumbar BMD loss of –0.6±1.9% was detectable equivalent to a –0.03±0.15 reduction of Z -scores per year (regression analysis). Impact of hormonal status: In the complete cohort, postmenopausal status was associated with significantly lower BMD levels compared to men ( p =0.0441). Women and men within the lowest tertile of sex hormone levels (LH, FSH, DHEAS, testosterone, progesterone, estradiol) did not exhibit significant differences in terms of lumbar BMD compared to those in the highest tertile. The mean annual bone loss was statistically indistinguishable between men and women. There was no significant correlation of sex hormone levels and BMD in men and premenopausal women. In postmenopausal women, however, low estradiol and high LH levels correlated with the extent of annual BMD loss ( p <0.05). Our data confirm significantly reduced lumbar T -scores in the very late period after renal transplantation. The lumbar BMD decreased by –0.6±1.9% per year. In postmenopausal long-term renal transplant recipients, low estradiol levels were associated with accelerated bone loss.The data were presented in part at the 37th annual meeting of the American Society of Nephrology, ASN 2004 (Renal Week 2004) 相似文献
11.
Rossini M Zanotti R Bonadonna P Artuso A Caruso B Schena D Vecchiato D Bonifacio M Viapiana O Gatti D Senna G Riccio A Passalacqua G Pizzolo G Adami S 《BONE》2011,49(4):880-885
Objective
We systematically assessed bone mineral density (BMD), bone turnover markers (BTM), and fractures in a large cohort of patients with Indolent Systemic Mastocytosis (ISM).Methods
Eighty-two patients (mean age 48 years, 37 women) with ISM were studied. BMD was measured by dual X-ray absorptiometry at the lumbar spine and proximal hip. The serum markers of bone turnover included bone-specific alkaline phosphatase, C-telopeptides of type I collagen, and serum osteocalcin. Previous clinical fractures were registered and spine X-ray was obtained from all patients.Results
Three women were excluded for concomitant diseases associated to osteoporosis. Osteoporosis according with the WHO classification (T-score < − 2.5) was found in 16 patients (20.0%) (7 females and 9 men). Mastocytosis-related low BMD (Z-score at either the spine or the hip < − 2) was found in 3 women (9%) and 13 men (28%). The BMD was generally lower at the spine than at the hip. No significant correlation was observed between serum tryptase levels and T or Z-score BMD. One or more moderate or severe vertebral fractures were found in 17 patients (12 men); in 11 of them Z-score values were > − 2 or not valuable at the spine. No significant difference was found in the prevalence of mastocytosis-related low BMD and/or vertebral fractures between patients with or without skin involvement. Two patients had radiographic and densitometric osteosclerosis-like characteristics. In osteoporotic patients higher, normal or lower serum BTM were found, without correlations with serum tryptase levels, while in patients with osteosclerosis both BTM and serum tryptase values were particularly increased.Conclusions
Vertebral osteoporosis and fractures are frequent in patients with ISM. Spine X-ray and densitometric examination are warranted in all patients, also without skin involvement and particularly in males; Z-score other than T-score BMD must be evaluated. Patients with idiopathic osteoporosis should be evaluated for mast cell disease. Both high than low BTM can be observed in patients with osteoporosis while osteosclerosis is characterized by high bone turnover and serum tryptase levels. 相似文献12.
各期慢性肾脏病患者骨代谢生化指标与骨密度的相关性 总被引:1,自引:0,他引:1
目的 观察各期慢性肾脏病(CKD)患者血清骨代谢生化指标与骨密度(BMD)的变化情况及其相关性,探讨这些指标在肾性骨营养不良(ROD)早期诊断中的意义。 方法 78例入选患者共分6组,其中Ccr≥15 ml/min者按CKD临床1~4期分期标准分为4组; Ccr <15 ml/min者按是否行规律血液透析而分为2组。ELISA法测定骨保护素(OPG)。放射免疫法测定血清骨钙素(OC)、降钙素(CT)。化学发光法测定甲状旁腺素(iPTH)。6组患者中共47例行腰椎及股骨不同部位BMD测定。分析各组患者以上指标的差异及其相关性。 结果 (1)血清OPG、iPTH及磷分别从CKD 3、4、5期开始显著上升(P < 0.01),其中OPG在血液透析后达(5.10±1.34)ng/L,显著高于透析前的(3.35±0.76) ng/L,差异有统计学意义(P < 0.05)。各期CKD患者血清OC、CT、钙及碱性磷酸酶水平差异无统计学意义,而血液透析可使OC显著升高(P < 0.05)。股骨沃德三角BMD在 CKD 4期患者下降至0.77±0.09,显著低于CKD 1期患者的1.15±0.05,差异有统计学意义(P < 0.01),而血液透析不影响其水平。(2)血清OPG与Ccr、磷、iPTH、OC呈负或正相关(r分别为-0.70、0.51、0.39、0.36,均P < 0.01)。股骨沃德三角BMD与血清iPTH、OC呈负相关(r分别为-0.59、-0.51,均P < 0.01);与血清磷、OPG亦呈负相关(r分别为-0.45、-0.48,均P < 0.05)。 结论 CKD患者骨代谢生化指标与BMD均随Ccr下降而出现明显异常,这些变化之间存在一定的相关性。血清OPG改变早于iPTH及BMD,在ROD的早期诊断中意义最大。血液透析可使血清OPG、OC水平升高,但不影响BMD水平。 相似文献
13.
绝经后骨质疏松症患者骨密度及骨代谢参数的调查研究 总被引:11,自引:1,他引:10
目的 了解E2和IL-6在骨质疏松症发病中的作用。方法 选择绝经后妇女120例,绝经后有骨质疏松60例(OP组),绝经后无骨质疏松60例(NOP组),另外选择绝经前妇女60例为对照组。对180名妇女雌二醇(E2)、骨密度(BMD)、白细胞介素-6(IL-6)、血清总碱性磷酸酶(ALP)、骨钙素(BGP)、尿羟脯氨酸肌酐比值(尿Hoc/Cr)、尿钙肌酐比值(尿Ca/Cr)等指标进行了测定。结果 绝经后妇女骨形成指标BGP及ALT明显高于对照组妇女,其中ALP在OP组和NOP组间有差异,而BGP在OP组和NOP组间无差异;绝经后妇女骨吸收指标尿HOP/Cr及尿Ca/Cr明显高于对照组妇女,OP组尿HOP/Cr及尿Ca/Cr又明显高于NOP组;绝经后妇女的血清E2的含量明显低于对照组(绝经前妇女),OP组又明显低于NOP组;绝经后妇女血清IL-6的含量明显高于对照组妇女,而OP组又明显高于NOP组。结论 本研究证明E2、IL-6与骨质疏松关系密切,雌激素水平的下降,IL-6分泌增多,是导致骨吸收加速的重要原因之一。 相似文献
14.
目的探讨类风湿关节炎(rheumatoid arthritis,RA)患者骨密度(bone mineral density,BMD)及骨代谢指标的相关影响因素,观察运动频率对RA伴发骨质疏松(osteoporosis,OP)患者BMD及骨代谢指标的影响。方法回顾性分析45例初诊RA患者的性别、年龄、病程、超敏C反应蛋白(high-sensitivity C-reactive protein,HS-CRP)、红细胞沉降率(erythrocyte sedimentation rate,ESR)、抗环瓜氨酸肽抗体(anti-cyclic cirullinated peptide antibodies,抗CCP抗体)、RA疾病活动性评分(DAS28评分)等指标,观察这些临床因素对RA患者的BMD及血清骨代谢指标的影响。血清骨代谢指标包括β-胶原降解产物(β-C-terminal telopeptide region of collagen type1,β-CTX)、总Ⅰ型胶原氨基端延长肽(I pro collagen N-terminal pro peptide,PINP)、骨钙素(osteocalcin,OC)、25羟维生素D[25-(OH)D],通过电话回访RA患者的康复运动情况,分析运动频率对RA伴OP患者骨密度及骨代谢指标的影响。结果本组RA伴发OP的发生率为46.67%,BMD的下降以腰椎、股骨颈最明显。BMD的改变与年龄、病程、DAS28评分相关,随着年龄的增长、病程的延长、DAS28评分的升高,BMD降低(P0.05)。骨吸收指标β-CTX在年龄≤65岁组、病程≤0.5年组、抗CCP抗体阳性组均升高,差异有统计学意义(P0.01,P0.05);骨形成指标PINP、OC在年龄≤65岁组、抗CCP抗体阳性组均升高,差异有统计学意义(P0.05);25-(OH)D水平在DAS28评分2.6组高于DAS28评分≥2.6组,差异有统计学意义(P0.05)。RA伴OP患者中,经常运动组的全身及腰椎BMD、PINP、OC均高于不运动组,差异有统计学意义(P0.05,P0.01);PINP、OC与经常运动呈正相关(P0.05),β-CTX与抗CCP抗体呈正相关(P0.01)。多元线性回归分析显示全身BMD受血清25-(OH)D水平及运动频率影响明显,随着血清25-(OH)D水平及运动频率的提高,全身BMD呈增加趋势。结论 RA伴发OP的发病率高,骨密度与年龄、病程、疾病的活动、25-(OH)D水平、运动频率相关。RA伴发OP属于高转换型骨代谢异常,在疾病早期、活动期骨破坏和骨形成均加快。运动可促进骨形成、提高骨密度,建议临床应重视在内科治疗基础上的运动治疗。 相似文献
15.
目的:为探讨甲亢患者骨密度与骨代谢指标的改变。方法:本文测定了118例甲亢患者腰椎(L2~4)及股骨上端(Neck、Ward三角、Troch)骨密度、血清骨钙素(BGP)、甲状旁腺素中间片段(PTH-m)及尿脱氧吡啶啉(Dpd)。结果:甲亢患者骨密度低于正常对照组,t检验具显著差异(p<0.01)、血清BGP及Dpd高于正常对照组,t检验具显著差异(p<0.01),与骨密度呈负相关r=-0.2135、-0.2050(p<0.05);而PTH-m低于正常对照组,与骨密度无相关性r=0.0830(p>0.05)。结论:甲亢为高转换型骨质疏松,BGP、Dpd可作为骨形成及骨吸收的敏感指标 相似文献
16.
There is an interplay between the cells in the bone marrow and the surrounding bone tissue, but little is known about the effects of myeloablative treatment followed by bone marrow transplantation on bone metabolism. We have therefore investigated 24 patients undergoing bone marrow transplantation (14 autologous, 10 allogeneic) for hematological malignancies. Serum concentrations of parathyroid hormone (PTH), albumin-modified calcium, and biomarkers for bone turnover-osteocalcin, bone alkaline phosphatase (B-ALP), and carboxyterminal cross-linked telopeptide of type I collagen (ICTP)-were measured. The samples were collected before myeloablative treatment, on the day of bone marrow infusion and 1, 2, 3, and 12 weeks thereafter. A serum PTH peak was consistently seen the day after total body irradiation, but no long-term effects on PTH/calcium homeostasis were observed. Bone formation as reflected by serum osteocalcin and B-ALP decreased, with nadir levels 2 to 3 weeks after marrow infusion. A simultaneous increase in bone resorption (increased S-ICTP) occurred. Pretreatment values were not completely regained 12 weeks after transplantation. the findings indicate that bone tissue is affected by myeloablative treatment, and the changes in biomarkers imply a net loss of bone over the study period. 相似文献
17.
目的探讨脂质运载蛋白2(lipocalin 2,LCN2)对老年2型糖尿病(type 2 diabetes mellitus,T2DM)患者骨代谢的影响。方法研究对象共119例,其中84例为老年T2DM患者,35例为非T2DM对照。采取静脉血检测空腹血糖(fasting plasma glucose,FPG)、糖化血红蛋白(glycosylated hemoglobin,Hb Alc)、25-羟维生素D[25(OH)D]、I型胶原交联羧基末端肽(collagen type 1 cross-linked C-telopeptide,CTX)、Ⅰ型前胶原氨基端延长肽(type 1 N-terminal procollagen,P1NP)、全段甲状旁腺素以及肌酐、血钙(Ca)、血磷(P)等指标,用ELISA法检测血清LCN2。用双能X线骨密度仪检测股骨颈和腰椎1~4(L1~4)的骨密度(bone mineral density,BMD)。结果老年T2DM患者血清LCN2水平高于非T2DM对照组(197.13±42.15 ng/m L vs172.29±54.71 ng/m L,P=0.01)。按照血清LCN2水平三分位数将T2DM患者分为3组。其中腰椎BMD、股骨颈BMD、P1NP和CTX伴随LCN2水平增高而增高,而FPG和Hb A1c伴随LCN2水平增高而降低(所有趋势P0.05)。Pearson相关性分析显示,LCN2和T2DM患者BMD呈正相关(股骨颈:r=0.350,P=0.001;腰椎:r=0.355,P=0.001),和骨转换标志物呈正相关(P1NP:r=0.354,P=0.001;CTX:r=0.438,P0.001),和糖代谢指标呈负相关(FPG:r=-0.321,P=0.003;Hb A1c:r=-0.342,P=0.002)。进一步回归分析显示,LCN2是T2DM患者腰椎BMD的影响因素(P0.05)。结论血清LCN2水平和老年T2DM患者骨代谢相关,LCN2水平增高可能有助于BMD的增加。 相似文献
18.
目的 观察促胰液素(secretin,SCT)对去卵巢骨质疏松大鼠骨转换指标和骨密度的影响。方法 采用双侧卵巢去除法制备绝经后骨质疏松大鼠模型,将60只SD大鼠随机分为假手术组、模型对照组、雌激素治疗组和促胰液素治疗组,每组各15只。干预3个月后,测定腰椎骨密度(bone mineral density,BMD),采取ELISA法测定血清I型胶原N前端肽(procollagen I N-Terminal propeptide,PINP)和I型胶原C末端肽(collagen type I C-terminal cross-linked telopeptide,CTX),另使用STRING10.0蛋白相互作用网络分析工具分析骨质疏松相关差异蛋白。结果 与假手术组比较,模型对照组、雌激素治疗组、促胰液素治疗组的PINP含量升高(P<0.05),模型对照组的CTX含量升高(P<0.05),模型对照组的BMD下降(P<0.05),雌激素治疗组和促胰液素治疗组的CTX、BMD含量无显著差异(P>0.05);与模型对照组比较,雌激素治疗组、促胰液素治疗组PINP、CTX含量有所下降,而BMD含量升高(P<0.05);雌激素组与促胰液素组之间PINP、CTX、BMD含量无显著差异(P>0.05)。结论 促胰液素能改善去卵巢骨质疏松大鼠的PINP和CTX含量,增加骨密度,抑制骨质丢失,具有较好的抗骨质疏松效果。 相似文献
19.
目的:研究绝经后女性血清骨桥蛋白(OPN)水平与骨密度(BMD)、骨标志物的关系,探索OPN在绝经后骨质疏松症( PMOP)中的临床应用价值。方法对125名绝经后女性进行研究,双能X线骨密度仪测量腰1-4及左股骨颈BMD,测定血中I型原胶原N-端前肽(PINP)、β-胶原降解产物(β-CTX)、25羟维生素D、甲状旁腺素、OPN、骨钙素(OC)、钙(Ca)和磷(P)。结果①骨质疏松组血清OPN水平明显高于骨量减少和正常组( F=0.118,P=0.000);②血清OPN水平与BMD(腰1-4,左股骨颈)、血Ca显著负相关,与年龄、β-CTX、OC显著正相关( P均<0.05);③多元线性回归分析结果表明,左股骨颈骨密度(B,-11.971;SE,2.383;标准系数,-0.402;P=0.000)、血钙(B,-6.696;SE,2.383;标准系数,-0.225;P=0.006)是OPN水平独立预测因子。结论高血清OPN水平与低BMD、高β-CTX水平及钙缺乏相关,该结果丰富了现有的临床证据,为防治PMOP提供了新的思路。 相似文献
20.
目的 测定新生儿血清骨代谢激素水平及探讨其临床意义。方法 采用放射免疫与免疫放射分析法测定89 例新生儿脐带血清,22 例出生3 天婴儿血清骨钙素(BGP)、降钙素(h-CT)和甲状旁腺素(iPTH)水平。结果 新生儿脐带血BGP、h-CT 和 iPTH 水平分别为 19.3±16.8 μg/L、78.9±51.5 ng/L 和0.22±0.16 pm ol/L(x±s),与分娩前母血比较,差异非常显著,P 值分别为P<0.01、P< 0.01 和P< 0.01;出生3 天婴儿血清BGP、h-CT 和iPTH 水平分别为7.4±2.3 μg/L、57.8±13.8 ng/L和5.6±1.69 pm ol/L(x±s),与新生儿脐带血比较差异非常显著,P 值分别为P< 0.01、P< 0.01 和P< 0.01。结论 本研究结果表明新生儿骨代谢激素的放射免疫测定是研究新生儿骨代谢变化的重要检测手段。 相似文献